top of page

As biosims win nods in Europe and India, debate over naming rights heats up

From www.fiercepharma.com

Drugmakers, biotechs and their generic rivals are squabbling over the names that will be assigned to biosimilars, in a battle for a marketing edge.

At issue is whether biosimilars should have the same International Proprietary Name, or INN, as brand name biologics. Brand-name drugmakers and biotechs want biosimilars to have unique, non-proprietary, or generic names to distinguish the medicines from the original biologics. As they see it, distinct names would lessen confusion in the marketplace and help to ensure patient safety.

"They should not all share the same name," says Geoff Eich, who heads global biosimilar regulatory policy at Amgen. "I want to know which product was given the patient so I can work with the physician to understand what may have gone awry. We need distinguishable names because that's what tells us who to contact."

But generic drug makers disagree and believe that creating a new standard for biosimilars would, in fact, create confusion and argue that pushing for separate names is a smokescreen to blunt the inroads that biosimilars are expected to make, especially in the lucrative U.S. market.

"Having the same name is clearly important for market uptake," says Richard Davies, the chief commercial officer at Hospira. "We see the naming argument more around whether the products are different, but they're not. … Having the same name will help with market formation."

Much of the debate focuses on whether different INNs would hamper substitution needed for lowering healthcare costs. Though biosimilars won't offer the same sort of savings as garden-variety generics, they are generally expected to cost only 70% to 80% of the branded biologic. There is also heated disagreement about the extent to which distinct INNs can make it possible to spot safety issues. Brand-name drugmakers insist that different INNs will make it easier to track adverse events that might appear in patient records and post-marketing reports. A survey of 376 prescribers conducted last year by the Alliance for Safe Biologics, a group supported by biotechnology companies, found that 86% prefer to report adverse events by product name.

Of course, a great deal of money is at stake. By 2020, global biosimilar sales may reach $25 billion, according to IMS Health, which expects the U.S. to become the cornerstone of worldwide demand once the FDA begins issuing approvals. Meanwhile, eight E.U. countries--Germany, France, Italy, the U.K., Spain, Sweden, Poland and Romania--could reap cumulative savings of anywhere from $16 billion to $45 billion between 2007 and 2020, according to the IGES Institut, a Germany-based healthcare consulting firm.

The naming debate is intensifying as more biosimilars become available. In Europe, more than a dozen such medicines have been approved since 2006, including several treatments for reducing infection during chemotherapy or for combating anemia caused by chronic kidney disease. And recently, the European Medicines Agency endorsed the first biosimilar monoclonal antibody therapy.

Meanwhile, the Generic Pharmaceutical Association filed a citizen's petition with the FDA to request that all biosimilars share the same INN as original biologics. And Novartis, which owns Sandoz, also filed such a petition. At the same time, Johnson & Johnson filed a petition arguing that biosimilar names should not be identical to the underlying biologic.

"Names that are similar but not the same will appropriately reflect the legal and scientific reality that biosimilars are similar to, but not the same as their reference products or other biosimilars," says Jay Siegel, chief biotech officer and head of scientific strategy and policy at J&J.

Featured Posts
Recent Posts

About pharmanaming.com

The Global Naming Network (GNN), headquartered in Geneva, is the world's largest network of independent naming and brand identity agencies.

 

With 16 offices and around 120 cooperating naming and branding specialists in 11  countries, from Shanghai to New York and from Seoul to Paris, GNN works for clients ranging from large multinationals to small startups all over the world.

​

Healthcare and pharmaceutical projects are coordinated from the GNN partner office of Readge consultants in Rijswijk.

 

Please get in touch for more information.

​

16

offices in 11 countries

​

120

creatives, strategists & consultants

​

GNN partners

China                     South Korea

France                   Italy
Germany               Japan

Netherlands         UK

India                      Singapore

Spain                     Canada

Switzerland          Russia

USA                       Dubai

5000

projects successfully executed

​

Pages

home                           name to brand

health & pharma        people

regulatory                   test & submit

India                            FDA

work                            blog

clients                         contact

>20000

linguistic professionals worldwide

​

Global Naming Network

© 2025 by Readge consultants

Leeuwendaallaan 24, 2281 GP Rijswijk, the Netherlands

call +31 653528944 or mail to pharma@globrands.com  

 

  • White LinkedIn Icon
bottom of page